0001485003-22-000098.txt : 20220727 0001485003-22-000098.hdr.sgml : 20220727 20220727080239 ACCESSION NUMBER: 0001485003-22-000098 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220727 ITEM INFORMATION: Other Events FILED AS OF DATE: 20220727 DATE AS OF CHANGE: 20220727 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sesen Bio, Inc. CENTRAL INDEX KEY: 0001485003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262025616 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36296 FILM NUMBER: 221108894 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET STREET 2: SUITE 1800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-444-8550 MAIL ADDRESS: STREET 1: 245 FIRST STREET STREET 2: SUITE 1800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Eleven Biotherapeutics, Inc. DATE OF NAME CHANGE: 20100223 8-K 1 sesn-20220727.htm 8-K sesn-20220727
False000148500300014850032022-07-272022-07-27

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 27, 2022
 
 
SESEN BIO, INC.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware001-3629626-2025616
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(I.R.S. Employer
Identification No.)
245 First Street, Suite 1800
Cambridge, MA
02142
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (617) 444-8550
Not Applicable
(Former name or former address, if changed since last report.)
 
 
Check the appropriate box below if the Form 8–K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)
 
☐Pre–commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))
 
☐Pre–commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))
 
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001SESNThe Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
                            Emerging growth company     ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                                 ¨


Item 8.01 – Other Events.

On July 26, 2022, Sesen Bio, Inc. (the “Company”) received approval from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) to transfer the listing of the Company’s common stock from the Nasdaq Global Market to the Nasdaq Capital Market (the “Approval”). As a result of the Approval, the Company has been granted a second 180-day grace period, or until January 23, 2023, to regain compliance with the minimum bid price requirement.

As previously disclosed, on January 24, 2022, the Company received written notice from Nasdaq indicating that the Company was not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1). The Company was given until July 25, 2022, to regain compliance with the minimum bid price requirement. In response, the Company submitted an application to transfer the listing of its common stock from the Nasdaq Global Market to the Nasdaq Capital Market.

The Company’s common stock will be transferred to the Nasdaq Capital Market effective at the opening of business on July 28, 2022, and will continue to trade under the symbol “SESN”. The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, and requires that listed companies meet certain financial and liquidity requirements and comply with Nasdaq’s corporate governance requirements.

To regain compliance with the minimum bid price requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Company’s common stock must be at least $1.00 for at least ten consecutive business days during the second 180-day grace period. If the Company does not regain compliance during this second grace period, its common stock would be subject to delisting by Nasdaq. As part of its transfer application, the Company notified Nasdaq that if its stock price does not recover sufficiently during the second grace period, it would implement a reverse stock split, if necessary.

As previously disclosed, Sesen Bio has initiated a process to review potential strategic alternatives with the goal of maximizing shareholder value. The Company believes that maintaining its listing on Nasdaq has the potential to enable a favorable strategic transaction by increasing the range and attractiveness of strategic alternatives that the Company is able to consider.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

This Current Report on Form 8-K contains forward-looking statements, including, but not limited to, statements regarding the Company’s ability to regain compliance with the minimum bid price requirement, the Company’s plans to implement a reverse stock split, if necessary, to regain compliance with the minimum bid price requirement and the Company’s belief that maintaining its listing on Nasdaq has the potential to enable a favorable strategic transaction by increasing the range and attractiveness of strategic alternatives that the Company is able to consider, which are based on the Company’s current expectations and inherently involve significant risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, including the risk that the Company may not meet the minimum bid price requirement during the second 180-day grace period or in the future, the risk that the Company may not otherwise meet the requirements for continued listing under the Nasdaq Listing Rules, the risk that Nasdaq may not grant the Company relief from delisting, if necessary, the risk that the Company may not be successful in identifying one or more strategic alternatives or ultimately pursuing a strategic alternative that delivers the anticipated benefits or enhances shareholder value, among other risks and uncertainties. A further description of the risks and uncertainties relating to the business of the Company is contained in the Company’s most recent annual report on Form 10-K and the Company’s quarterly reports on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the Securities and Exchange Commission. The Company undertakes no duty or obligation to update any forward-looking statements contained in this report as a result of new information, future events or changes in its expectations.



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 27, 2022
 
Sesen Bio, Inc.
By:
/s/ Thomas R. Cannell, D.V.M.
Thomas R. Cannell, D.V.M.
President and Chief Executive Officer



 EX-101.SCH 2 sesn-20220727.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 sesn-20220727_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 4 sesn-20220727_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Jul. 27, 2022
Cover [Abstract]  
Document Type 8-K
Entity Registrant Name SESEN BIO, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36296
Entity Tax Identification Number 26-2025616
Entity Address, Address Line One 245 First Street
Entity Address, Address Line Two Suite 1800
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code 617
Local Phone Number 444-8550
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol SESN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001485003
Amendment Flag false
Document Period End Date Jul. 27, 2022
XML 6 sesn-20220727_htm.xml IDEA: XBRL DOCUMENT 0001485003 2022-07-27 2022-07-27 false 0001485003 8-K 2022-07-27 SESEN BIO, INC. DE 001-36296 26-2025616 245 First Street Suite 1800 Cambridge MA 02142 617 444-8550 false false false false Common Stock, par value $0.001 SESN NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 23 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.sesenbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports sesn-20220727.htm sesn-20220727.xsd sesn-20220727_lab.xml sesn-20220727_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sesn-20220727.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "sesn-20220727.htm" ] }, "labelLink": { "local": [ "sesn-20220727_lab.xml" ] }, "presentationLink": { "local": [ "sesn-20220727_pre.xml" ] }, "schema": { "local": [ "sesn-20220727.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sesn", "nsuri": "http://www.sesenbio.com/20220727", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sesn-20220727.htm", "contextRef": "ibbb73737654846029e5f5a12c97a5ce0_D20220727-20220727", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.sesenbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sesn-20220727.htm", "contextRef": "ibbb73737654846029e5f5a12c97a5ce0_D20220727-20220727", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0001485003-22-000098-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001485003-22-000098-xbrl.zip M4$L#!!0 ( %- ^U30"[,5=QD +FD 1 9) MO$M43L:RP,F$%SF[IHN<)#J*K/$UUU6= ['D\FD.I&J<=(_%'1=/YS2=RKY2W5_NO3> MU$X"]J;("]*A'P5^1*A>RM>GJ;\I7Y'GA=':88CA]P5DG$I M<992PN=J/[Y9*.,P2W"4>G$2X@S:AHJ@<+S&2<)"/INEO2\3D>= GX)X6P5( MY&^K-$\KO2P\Y'Q]S^OTL8W3V]>G:^\OZ9X^+5]UR9T<+--2)_" "I[7NQ[@ MJ/^A0B+N\J("#4RP>_0^)!E&-"E'_COV;SY43N(H [/EK-D(1''R3Q\J&9EF MAZR]#X_^]K>_O<_\+"!'*4DCCAHLKXKJ^\/\R_>'>=9V[,Z.WKO^#4JS64 ^ M5%P_'05X5H_BB( _K1.7R1)_J?ONB1B?\)S$WPG\9V\_&G6(=Z'BF_;MBK! M?S6P9;G&BSI1/ 4+HJ.K6'$(_ZU1BG(K4P5%.*1%$[]^#.[H4I<\#7"_@O*F MA6RG6=WSI\3E/!Q0]?LN?.E*7V=V([[Y+'9NNI(Q=H?-F]Z9/FP/FWRO<3WI M774&;]87-NSONSSY(9=.?QU#P[5XRSK]== MZUKJ#<_YMN5,NA9]QYF;C?ZD*W:GQMR1C4#C/XN]6??*J9EGEW,S_!2:<_,: MGHMFPY%Z84LPKCJ^:7T==H>G06]HS,RK\QOW[-2WSRYK7;$Y,\-+P6PTYT;# M@#0ML=WHSXSAI] 8MD3#Z@UZ9YWK[KQ,\Q7*4J*>-1IVK9;8LRYYJ,?$F'=Y M8]B5VXW6S B[D+X[-KF1D7_/2SY2B&Y0C?7-V615M4.-O3 M%( =1>5T7B.

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